Needham & Company Reiterates a 'Buy' on Vertex (VRTX); Incivek Sales Continue to Fall, But Initial ALS-2200 Data Are Encouraging
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $540.26 -2.14%
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Rating Summary:
38 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 15 | New: 40
Join SI Premium – FREE
Needham & Company reiterates a 'Buy' on Vertex (NASDAQ: VRTX) price target of $65.00.
Analyst, Alan Carr, said, "U.S. Incivek sales of $328M fell short of our $344M and consensus ~$360M estimates. Kalydeco U.S. net sales were $46M, compared to our $50M estimate and consensus $41M. The company reported $(0.31) GAAP EPS, compared to our $0.59 estimate and consensus $0.57, driven mostly by a $78M excess Incivek inventory charge. Management lowered Incivek sales guidance by $400-450M to $1.1-1.25B. Despite the anticipated challenges with Incivek, we believe the stock is attractive due to progress with the CF programs. An impressive 4.54 log decline with 7 days ALS-2200 is encouraging, but we await results from longer-term combination trials."
FY12 EPS estimate chopped from $1.73 to $0.34 and FY13 from $0.87 to $0.33.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $49.96 yesterday.
Analyst, Alan Carr, said, "U.S. Incivek sales of $328M fell short of our $344M and consensus ~$360M estimates. Kalydeco U.S. net sales were $46M, compared to our $50M estimate and consensus $41M. The company reported $(0.31) GAAP EPS, compared to our $0.59 estimate and consensus $0.57, driven mostly by a $78M excess Incivek inventory charge. Management lowered Incivek sales guidance by $400-450M to $1.1-1.25B. Despite the anticipated challenges with Incivek, we believe the stock is attractive due to progress with the CF programs. An impressive 4.54 log decline with 7 days ALS-2200 is encouraging, but we await results from longer-term combination trials."
FY12 EPS estimate chopped from $1.73 to $0.34 and FY13 from $0.87 to $0.33.
For an analyst ratings summary and ratings history on Vertex click here. For more ratings news on Vertex click here.
Shares of Vertex closed at $49.96 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
- NRW Holdings Ltd. (NWH:AU) PT Raised to AUD8.47 at Canaccord
- Emkay Global Starts Pearl Global Industries (PGIL:IN) at Buy (1)
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
